Income Statement Xunfei Healthcare Technology Co., Ltd.
Stocks
2506
CNE100006MP5
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.10 HKD | -4.23% |
|
-2.47% | -12.64% |
| 06-17 | Xunfei Healthcare Technology Co., Ltd. Enters into A Memorandum of Understanding with Pt Dsst Mas Gemilang | CI |
| 03-30 | Xunfei Healthcare's Loss Narrows 51% in 2025; Shares Slip 5% | MT |
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Revenues | 372M | 472M | 556M | 734M | 915M |
Total Revenues | 372M | 472M | 556M | 734M | 915M |
Cost of Goods Sold, Total | 185M | 241M | 241M | 330M | 453M |
Gross Profit | 188M | 231M | 315M | 404M | 462M |
Selling General & Admin Expenses, Total | 160M | 269M | 276M | 288M | 309M |
Provision for Bad Debts | 154K | 8.76M | 5.83M | 12.4M | 34.54M |
R&D Expenses | 160M | 242M | 264M | 272M | 245M |
Other Operating Expenses, Total | 320M | 520M | 545M | 572M | 588M |
Operating Income | -132M | -289M | -231M | -168M | -127M |
Interest Expense, Total | -2.9M | -590K | -1.21M | -6.14M | -11.44M |
Interest And Investment Income | 1.81M | 3.14M | 7.96M | 6.42M | 11.15M |
Net Interest Expenses | -1.09M | 2.55M | 6.75M | 278K | -293K |
Income (Loss) On Equity Invest. | - | - | - | - | -2.86M |
Currency Exchange Gains (Loss) | - | - | - | - | 5.47M |
Other Non Operating Income (Expenses) | 22.47M | 39.55M | 36.22M | -4.43M | 28.36M |
EBT, Excl. Unusual Items | -111M | -247M | -188M | -172M | -96.07M |
Gain (Loss) On Sale Of Investments | - | 2.73M | 904K | 318K | 120K |
Gain (Loss) On Sale Of Assets | -144K | 12K | -33K | -18K | -36K |
Other Unusual Items | - | - | - | 25K | - |
EBT, Incl. Unusual Items | -111M | -244M | -187M | -172M | -95.98M |
Income Tax Expense | -21.57M | -35.5M | -32.69M | -34.38M | -30.22M |
Earnings From Continuing Operations | -89.4M | -209M | -154M | -138M | -65.77M |
Net Income to Company | -89.4M | -209M | -154M | -138M | -65.77M |
Minority Interest | 5.69M | 19.2M | 9.38M | 5.04M | 979K |
Net Income - (IS) | -83.71M | -189M | -145M | -133M | -64.79M |
Net Income to Common Incl Extra Items | -83.71M | -189M | -145M | -133M | -64.79M |
Net Income to Common Excl. Extra Items | -83.71M | -189M | -145M | -133M | -64.79M |
Per Share Items | |||||
Net EPS - Basic | -0.9 | -1.71 | -1.3 | -1.16 | -0.54 |
Basic EPS - Continuing Operations | -0.9 | -1.71 | -1.3 | -1.16 | -0.54 |
Basic Weighted Average Shares Outstanding | 93.36M | 111M | 111M | 114M | 121M |
Net EPS - Diluted | -0.9 | -1.71 | -1.3 | -1.16 | -0.54 |
Diluted EPS - Continuing Operations | -0.9 | -1.71 | -1.3 | -1.16 | -0.54 |
Diluted Weighted Average Shares Outstanding | 93.36M | 111M | 111M | 114M | 121M |
Normalized Basic EPS | -0.68 | -1.22 | -0.97 | -0.9 | -0.49 |
Normalized Diluted EPS | -0.68 | -1.22 | -0.97 | -0.9 | -0.49 |
Supplemental Items | |||||
EBITDA | -103M | -251M | -205M | -136M | -94.79M |
EBITA | -105M | -255M | -212M | -145M | -104M |
EBIT | -132M | -289M | -231M | -168M | -127M |
Effective Tax Rate - (Ratio) | 19.44 | 14.55 | 17.49 | 19.99 | 31.48 |
Current Domestic Taxes | - | - | - | 1.66M | 318K |
Total Current Taxes | - | - | - | 1.66M | 318K |
Deferred Domestic Taxes | -21.57M | -35.5M | -32.69M | -36.04M | -30.54M |
Total Deferred Taxes | -21.57M | -35.5M | -32.69M | -36.04M | -30.54M |
Normalized Net Income | -63.57M | -135M | -108M | -103M | -59.06M |
Interest on Long-Term Debt | 122K | 82K | 35K | 145K | 245K |
Supplemental Operating Expense Items | |||||
Advertising Expense | 3.44M | 8.14M | 16.76M | - | - |
Selling and Marketing Expenses | 90.65M | 160M | 163M | 192M | 207M |
General and Administrative Expenses | 69.35M | 109M | 113M | 95.88M | 102M |
Research And Development Expense From Footnotes | 160M | 242M | 264M | 272M | 245M |
Stock-Based Comp., COGS (Total) | - | - | - | - | 19.51M |
Stock-Based Comp., R&D Exp. (Total) | 9.91M | 26.38M | 25.12M | - | - |
Stock-Based Comp., S&M Exp. (Total) | 4.43M | 13.23M | 11.58M | - | - |
Stock-Based Comp., G&A Exp. (Total) | 20.56M | 57.04M | 56.63M | - | - |
Stock-Based Comp., Other (Total) | - | - | - | 54.63M | 7.27M |
Total Stock-Based Compensation | 34.9M | 96.65M | 93.33M | 54.63M | 26.78M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















